These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37848886)

  • 1. Ethical and coordinative challenges in setting up a national cohort study during the COVID-19 pandemic in Germany.
    Tilch K; Hopff SM; Appel K; Kraus M; Lorenz-Depiereux B; Pilgram L; Anton G; Berger S; Geisler R; Haas K; Illig T; Krefting D; Lorbeer R; Mitrov L; Muenchhoff M; Nauck M; Pley C; Reese JP; Rieg S; Scherer M; Stecher M; Stellbrink C; Valentin H; Winter C; Witzenrath M; Vehreschild JJ
    BMC Med Ethics; 2023 Oct; 24(1):84. PubMed ID: 37848886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of acute COVID-19 including chronic morbidity: protocol for the deep phenotyping National Pandemic Cohort Network in Germany (NAPKON-HAP).
    Steinbeis F; Thibeault C; Steinbrecher S; Ahlgrimm Y; Haack IA; August D; Balzuweit B; Bellinghausen C; Berger S; Chaplinskaya-Sobol I; Cornely O; Doeblin P; Endres M; Fink C; Finke C; Frank S; Hanß S; Hartung T; Hellmuth JC; Herold S; Heuschmann P; Heyckendorf J; Heyder R; Hippenstiel S; Hoffmann W; Kelle SU; Knape P; Koehler P; Kretzler L; Leistner DM; Lienau J; Lorbeer R; Lorenz-Depiereux B; Lüttke CD; Mai K; Merle U; Meyer-Arndt LA; Miljukov O; Muenchhoff M; Müller-Plathe M; Neuhann J; Neuhauser H; Nieters A; Otte C; Pape D; Pinto RM; Pley C; Pudszuhn A; Reuken P; Rieg S; Ritter P; Rohde G; Rönnefarth M; Ruzicka M; Schaller J; Schmidt A; Schmidt S; Schwachmeyer V; Schwanitz G; Seeger W; Stahl D; Stobäus N; Stubbe HC; Suttorp N; Temmesfeld B; Thun S; Triller P; Trinkmann F; Vadasz I; Valentin H; Vehreschild M; von Kalle C; von Lilienfeld-Toal M; Weber J; Welte T; Wildberg C; Wizimirski R; Zvork S; Sander LE; Vehreschild J; Zoller T; Kurth F; Witzenrath M
    Infection; 2024 Feb; 52(1):93-104. PubMed ID: 37434025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Integration of Inventory Data from Cohort and Registry Studies into an Existing Research Network: National Pandemic Cohort Network (NAPKON)].
    Hofmann AL; Vehreschild JJ; Witzenrath M; Hoffmann W; Illig T; Schreiber S; Anton G; Hellmuth JC; Muenchhoff M; Scherer C; Pley C; Thibeault C; Kurth F; Berger S; Hummel M; Hopff SM; Stecher M; Appel K; Stahl D; Kraus M; Lorenz-Depiereux B; Hanß S; von Kielmansegg S; Schlünder I; Niemeyer A; Heuschmann P; Krawczak M; Reese JP
    Gesundheitswesen; 2024 Oct; 86(10):647-654. PubMed ID: 39173676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics.
    Schons M; Pilgram L; Reese JP; Stecher M; Anton G; Appel KS; Bahmer T; Bartschke A; Bellinghausen C; Bernemann I; Brechtel M; Brinkmann F; Brünn C; Dhillon C; Fiessler C; Geisler R; Hamelmann E; Hansch S; Hanses F; Hanß S; Herold S; Heyder R; Hofmann AL; Hopff SM; Horn A; Jakob C; Jiru-Hillmann S; Keil T; Khodamoradi Y; Kohls M; Kraus M; Krefting D; Kunze S; Kurth F; Lieb W; Lippert LJ; Lorbeer R; Lorenz-Depiereux B; Maetzler C; Miljukov O; Nauck M; Pape D; Püntmann V; Reinke L; Römmele C; Rudolph S; Sass J; Schäfer C; Schaller J; Schattschneider M; Scheer C; Scherer M; Schmidt S; Schmidt J; Seibel K; Stahl D; Steinbeis F; Störk S; Tauchert M; Tebbe JJ; Thibeault C; Toepfner N; Ungethüm K; Vadasz I; Valentin H; Wiedmann S; Zoller T; Nagel E; Krawczak M; von Kalle C; Illig T; Schreiber S; Witzenrath M; Heuschmann P; Vehreschild JJ;
    Eur J Epidemiol; 2022 Aug; 37(8):849-870. PubMed ID: 35904671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term health sequelae and quality of life at least 6 months after infection with SARS-CoV-2: design and rationale of the COVIDOM-study as part of the NAPKON population-based cohort platform (POP).
    Horn A; Krist L; Lieb W; Montellano FA; Kohls M; Haas K; Gelbrich G; Bolay-Gehrig SJ; Morbach C; Reese JP; Störk S; Fricke J; Zoller T; Schmidt S; Triller P; Kretzler L; Rönnefarth M; Von Kalle C; Willich SN; Kurth F; Steinbeis F; Witzenrath M; Bahmer T; Hermes A; Krawczak M; Reinke L; Maetzler C; Franzenburg J; Enderle J; Flinspach A; Vehreschild J; Schons M; Illig T; Anton G; Ungethüm K; Finkenberg BC; Gehrig MT; Savaskan N; Heuschmann PU; Keil T; Schreiber S
    Infection; 2021 Dec; 49(6):1277-1287. PubMed ID: 34642875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The COVID-19 Pandemic as an Opportunity and Challenge for Registries in Health Services Research: Lessons Learned from the Lean European Open Survey on SARS-CoV-2 Infected Patients (LEOSS)].
    Pilgram L; Schons M; Jakob CEM; Claßen AY; Franke B; Tscharntke L; Schulze N; Fuhrmann S; Sauer G; de Miranda SMN; Prasser F; Stecher M; Vehreschild JJ
    Gesundheitswesen; 2021 Nov; 83(S 01):S45-S53. PubMed ID: 34731893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National strategy for palliative care of severely ill and dying people and their relatives in pandemics (PallPan) in Germany - study protocol of a mixed-methods project.
    Bausewein C; Hodiamont F; Berges N; Ullrich A; Gerlach C; Oechsle K; Pauli B; Weber J; Stiel S; Schneider N; Krumm N; Rolke R; Gebel C; Jansky M; Nauck F; Wedding U; van Oorschot B; Roch C; Werner L; Fischer M; Schallenburger M; Reuters MC; Schwartz J; Neukirchen M; Gülay A; Maus K; Jaspers B; Radbruch L; Heckel M; Klinger I; Ostgathe C; Kriesen U; Junghanß C; Lehmann E; Gesell D; Gauder S; Boehlke C; Becker G; Pralong A; Strupp J; Leisse C; Schloesser K; Voltz R; Jung N; Simon ST;
    BMC Palliat Care; 2022 Jan; 21(1):10. PubMed ID: 35027041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global Consortium Study of Neurological Dysfunction in COVID-19 (GCS-NeuroCOVID): Study Design and Rationale.
    Frontera J; Mainali S; Fink EL; Robertson CL; Schober M; Ziai W; Menon D; Kochanek PM; Suarez JI; Helbok R; McNett M; Chou SH;
    Neurocrit Care; 2020 Aug; 33(1):25-34. PubMed ID: 32445105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retracing the COVID-19 Pandemic in Germany from a Public Perspective using Google Search Queries Related to "coronavirus".
    Schuster B; Tizek L; Schielein MC; Ziehfreund S; Rothe K; Spinner CD; Biedermann T; Zink A
    Gesundheitswesen; 2021 May; 83(5):e9-e14. PubMed ID: 33862647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
    Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
    Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjusting working conditions and evaluating the risk of infection during the COVID-19 pandemic in different workplace settings in Germany: a study protocol for an explorative modular mixed methods approach.
    Rind E; Kimpel K; Preiser C; Papenfuss F; Wagner A; Alsyte K; Siegel A; Klink A; Steinhilber B; Kauderer J; Rieger MA
    BMJ Open; 2020 Nov; 10(11):e043908. PubMed ID: 33208339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact and Consequences of SARS-CoV-2 Pandemic on a Single University Dermatology Outpatient Clinic in Germany.
    Wang R; Helf C; Tizek L; Neuhauser R; Eyerich K; Zink A; Eberlein B; Biedermann T; Brockow K; Boehner A
    Int J Environ Res Public Health; 2020 Aug; 17(17):. PubMed ID: 32858870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal Household Assessment of Respiratory Illness in Children and Parents During the COVID-19 Pandemic.
    de Hoog MLA; Sluiter-Post JGC; Westerhof I; Fourie E; Heuvelman VD; Boom TT; Euser SM; Badoux P; Reusken C; Bont LJ; Sanders EAM; Jaddoe VWV; Herpers BL; Eggink D; Wildenbeest JG; Duijts L; van Houten MA; Bruijning-Verhagen PCJL
    JAMA Netw Open; 2022 Oct; 5(10):e2237522. PubMed ID: 36264578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethics committees in the time of COVID-19.
    Monaco E; Pisano L; Nasato L; Lorenzoni G; Gregori D; Martinato M
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):113-118. PubMed ID: 33412801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in Human Research Ethics Committee and governance processes throughout Australia: a need for a uniform approach.
    Dudi-Venkata NN; Cox DRA; Marson N; Tan L; Pockney P; Muralidharan V; Watson DI; Richards T;
    ANZ J Surg; 2021 Nov; 91(11):2263-2268. PubMed ID: 33851489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial measurements in COVID-19-induced acute respiratory disease to unravel heterogeneity of the disease course: design of the Maastricht Intensive Care COVID cohort (MaastrICCht).
    Tas J; van Gassel RJJ; Heines SJH; Mulder MMG; Heijnen NFL; Acampo-de Jong MJ; Bels JLM; Bennis FC; Koelmann M; Groven RVM; Donkers MA; van Rosmalen F; Hermans BJM; Meex SJ; Mingels A; Bekers O; Savelkoul P; Oude Lashof AML; Wildberger J; Tijssen FH; Buhre W; Sels JEM; Ghossein-Doha C; Driessen RGH; Kubben PL; Janssen MLF; Nicolaes GAF; Strauch U; Geyik Z; Delnoij TSR; Walraven KHM; Stehouwer CD; Verbunt JAMCF; Van Mook WNKA; van Santen S; Schnabel RM; Aries MJH; van de Poll MCG; Bergmans D; van der Horst ICC; van Kuijk S; van Bussel BCT
    BMJ Open; 2020 Sep; 10(9):e040175. PubMed ID: 32994259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.